Last reviewed · How we verify
QNASL
At a glance
| Generic name | QNASL |
|---|---|
| Sponsor | University of Chicago |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Nasal Discomfort
- Headache
- Epistaxis
- Pyrexia
- Upper Respiratory Tract Infection
- Nasopharyngitis
- Nasal Ulcerations
Serious adverse events
- Epistaxis (Severe)
Key clinical trials
- Study in Adult Patients With Moderate to Severe Asthma (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting (STRENGTH)
- Directed Topical Drug Delivery for Treatment for PASC Hyposmia (PHASE2)
- Efficacy and Safety of CHF 1535 200/6µg in Not Adequately Controlled Asthmatic Patients (PHASE3)
- Fixed Triple Inhaled Combination in Asthmatic Patients in a Real-life Setting
- Triple Therapy in Real-life: Impact on Adherence and Health Status (TRITRIAL)
- Effects of Beclometasone Dipropionate/Formoterol Fumarate Via NEXT(Haler) in a Real-world Study on Asthma Control
- Biomarkers for Predicting the Response to Inhaled Corticosteroid in Patients With Chronic Cough. (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |